Gender, obesity and repeated elevation of C-reactive protein: Data from the CARDIA cohort

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Ishii, Shinya ^a   Karlamangla, Arun S ^b   Bote, Marcos ^c   Irwin, Michael R ^d   Jacobs, David R ^e   Cho, Hyong Jin ^d   Seeman, Teresa E ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MURCIA   (Spain)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; SEX HORMONE;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG USE; FEMALE; GENDER; HIGH RISK POPULATION; HUMAN; INFLAMMATION; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; OBESITY; PROTEIN BLOOD LEVEL; BLOOD; COHORT ANALYSIS; CORONARY ARTERY DISEASE; METABOLISM; MULTIVARIATE ANALYSIS; RISK; RISK FACTOR; SEXUAL DEVELOPMENT; STATISTICS; UNITED STATES;

ADULT; BODY MASS INDEX; C-REACTIVE PROTEIN; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; OBESITY; ODDS RATIO; RISK FACTORS; SEX CHARACTERISTICS; STATISTICS AS TOPIC; UNITED STATES;

EID: 84860475785     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036062     Document Type: Article

References (41)

1. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499-511.
2. Myers GL, Rifai N, Tracy RP, Roberts WL, Alexander RW, et al. (2004) CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group. Circulation 110: e545-549.
3. Ridker PM, (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107: 363-369.
4. Ridker PM, Cook N, (2004) Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 109: 1955-1959.
5. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB, (1999) Elevated C-reactive protein levels in overweight and obese adults. Jama 282: 2131-2135.
6. Alley DE, Seeman TE, Ki Kim J, Karlamangla A, Hu P, et al. (2006) Socioeconomic status and C-reactive protein levels in the US population: NHANES IV. Brain Behav Immun 20: 498-504.
7. Nazmi A, Oliveira IO, Victora CG, (2008) Correlates of C-reactive protein levels in young adults: a population-based cohort study of 3827 subjects in Brazil. Braz J Med Biol Res 41: 357-367.
8. Hamer M, Chida Y, Stamatakis E, (2009) Association of very highly elevated C-reactive protein concentration with cardiovascular events and all-cause mortality. Clin Chem 56: 132-135.
9. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, et al. (2005) C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 112: 25-31.
10. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR, (1999) C-reactive protein and outcome after ischemic stroke. Stroke 30: 981-985.
11. Cutter GR, Burke GL, Dyer AR, Friedman GD, Hilner JE, et al. (1991) Cardiovascular risk factors in young adults. The CARDIA baseline monograph. Control Clin Trials 12: 1S-77S.
12. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, et al. (1988) CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 41: 1105-1116.
13. Sidney S, Jacobs DR Jr, Haskell WL, Armstrong MA, Dimicco A, et al. (1991) Comparison of two methods of assessing physical activity in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol 133: 1231-1245.
14. Khera A, Vega GL, Das SR, Ayers C, McGuire DK, et al. (2009) Sex differences in the relationship between C-reactive protein and body fat. J Clin Endocrinol Metab 94: 3251-3258.
15. Chenillot O, Henny J, Steinmetz J, Herbeth B, Wagner C, et al. (2000) High sensitivity C-reactive protein: biological variations and reference limits. Clin Chem Lab Med 38: 1003-1011.
16. O'Connor MF, Bower JE, Cho HJ, Creswell JD, Dimitrov S, et al. (2009) To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav Immun 23: 887-897.
17. Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, et al. (2005) Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 46: 1417-1424.
18. Groblewska M, Mroczko B, Wereszczynska-Siemiatkowska U, Kedra B, Lukaszewicz M, et al. (2008) Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 46: 1423-1428.
19. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, et al. (2006) C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 24: 5216-5222.
20. Heikkila K, Ebrahim S, Lawlor DA, (2007) A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 61: 824-833.
21. Hastie T, Tibshirani R, Friedman J, (2009) The Elements of Statistical Learning: Data Mining, Inference, and Prediction. New York, NY Springer.
22. Harrell FE, (2001) Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY Springer.
23. Izenman AJ, (2008) Modern Multivariate Statistical Techniques: Regression, Classification, Manifold Learning. New York, NY Springer.
24. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK, (2003) Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 138: 891-897.
25. Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, et al. (2004) Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation 109: 3022-3028.
26. Lloyd-Jones DM, Liu K, Colangelo LA, Yan LL, Klein L, et al. (2007) Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. Circulation 115: 1004-1011.
27. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama 289: 2560-2572.
28. Rodgers JR, Rodgers JL, (1993) Chronic Poverty in the United States. The Journal of Human Resources 28: 25-54.
29. Karlamangla AS, Singer BH, Williams DR, Schwartz JE, Matthews KA, et al. (2005) Impact of socioeconomic status on longitudinal accumulation of cardiovascular risk in young adults: the CARDIA Study (USA). Soc Sci Med 60: 999-1015.
30. Macintyre S, Hunt K, (1997) Socio-economic Position, Gender and Health: How Do They Interact? J Health Psychol 2: 315-334.
31. Black PH, (2003) The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun 17: 350-364.
32. Goldstein DS, (1995) Stress, Catecholamines, and Cardiovascular Disease: Oxford University Press.
33. Bjorntorp P, (2001) Do stress reactions cause abdominal obesity and comorbidities? Obes Rev 2: 73-86.
34. Calabro P, Chang DW, Willerson JT, Yeh ET, (2005) Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 46: 1112-1113.
35. Lakoski SG, Brosnihan B, Herrington DM, (2005) Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial. Am Heart J 150: 907-911.
36. Hu P, Greendale GA, Palla SL, Reboussin BA, Herrington DM, et al. (2006) The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis 185: 347-352.
37. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, et al. (2004) Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 150: 161-171.
38. Falagas ME, Kompoti M, (2006) Obesity and infection. Lancet Infect Dis 6: 438-446.
39. Ruhl CE, Everhart JE, Ding J, Goodpaster BH, Kanaya AM, et al. (2004) Serum leptin concentrations and body adipose measures in older black and white adults. Am J Clin Nutr 80: 576-583.
40. Cartier A, Cote M, Lemieux I, Perusse L, Tremblay A, et al. (2009) Sex differences in inflammatory markers: what is the contribution of visceral adiposity? Am J Clin Nutr 89: 1307-1314.
41. Gabay C, Kushner I, (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454.